Sensei Biotherapeutics Shares Surge on Acquisition, Private Placement

Dow Jones

02/19

By Josh Beckerman

Sensei Biotherapeutics shares surged as it acquired Faeth Therapeutics and entered an agreement for a $200 million private placement.

The stock rose 177% to $25.32 and is up about 169% for the past 52 weeks.

Investors include B Group Capital, Balyasny Asset Management, Columbia Threadneedle Investments, Cormorant Asset Management, Fairmount, Logos Capital, RA Capital Management, Vivo Capital and others.

Faeth is developing drugs that target tumor metabolism and signaling.

On Oct. 17, cancer-focused Sensei reported results from the dose expansion portion of its Phase 1/2 trial evaluating solnerstotug. "We believe solnerstotug's emerging dose-dependent activity in refractory 'hot' tumors, combined with a favorable tolerability profile, support its advancement into Phase 2 studies," the company said at the time.

Sensei said on Oct. 30 that it would discontinue development of solnerstotug, review strategic alternatives and implement a workforce reduction.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

February 18, 2026 13:51 ET (18:51 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2612423560"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612423560\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612423560?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-19 02:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612423560","market":"nz","top_or_hot":-1,"title":"Sensei Biotherapeutics Shares Surge on Acquisition, Private Placement","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/SNSE\">Sensei Biotherapeutics</a> shares surged as it acquired Faeth <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> and entered an agreement for a $200 million private placement. \n</p>\n<p>\n  The stock rose 177% to $25.32 and is up about 169% for the past 52 weeks. \n</p>\n<p>\n  Investors include B Group Capital, Balyasny Asset Management, Columbia Threadneedle Investments, Cormorant Asset Management, Fairmount, Logos Capital, RA Capital Management, Vivo Capital and others. \n</p>\n<p>\n  Faeth is developing drugs that target tumor metabolism and signaling. \n</p>\n<p>\n  On Oct. 17, cancer-focused Sensei reported results from the dose expansion portion of its Phase 1/2 trial evaluating solnerstotug. \"We believe solnerstotug's emerging dose-dependent activity in refractory 'hot' tumors, combined with a favorable tolerability profile, support its advancement into Phase 2 studies,\" the company said at the time. \n</p>\n<p>\n  Sensei said on Oct. 30 that it would discontinue development of solnerstotug, review strategic alternatives and implement a workforce reduction. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 18, 2026 13:51 ET (18:51 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sensei Biotherapeutics Shares Surge on Acquisition, Private Placement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSensei Biotherapeutics Shares Surge on Acquisition, Private Placement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-19 02:51</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/SNSE\">Sensei Biotherapeutics</a> shares surged as it acquired Faeth <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> and entered an agreement for a $200 million private placement. \n</p>\n<p>\n  The stock rose 177% to $25.32 and is up about 169% for the past 52 weeks. \n</p>\n<p>\n  Investors include B Group Capital, Balyasny Asset Management, Columbia Threadneedle Investments, Cormorant Asset Management, Fairmount, Logos Capital, RA Capital Management, Vivo Capital and others. \n</p>\n<p>\n  Faeth is developing drugs that target tumor metabolism and signaling. \n</p>\n<p>\n  On Oct. 17, cancer-focused Sensei reported results from the dose expansion portion of its Phase 1/2 trial evaluating solnerstotug. \"We believe solnerstotug's emerging dose-dependent activity in refractory 'hot' tumors, combined with a favorable tolerability profile, support its advancement into Phase 2 studies,\" the company said at the time. \n</p>\n<p>\n  Sensei said on Oct. 30 that it would discontinue development of solnerstotug, review strategic alternatives and implement a workforce reduction. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 18, 2026 13:51 ET (18:51 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNSE","symbol_name":"Sensei Biotherapeutics, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2612423560","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612423560","pubTimestamp":1771440660,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Sensei Biotherapeutics shares surged as it acquired Faeth Therapeutics and entered an agreement for a $200 million private placement.The stock rose 177% to $25.32 and is up about 169% for the past 52 weeks.Investors include B Group Capital, Balyasny Asset Management, Columbia Threadneedle Investments, Cormorant Asset Management, Fairmount, Logos Capital, RA Capital Management, Vivo Capital and others.Faeth is developing drugs that target tumor metabolism and signaling.On Oct. 17, cancer-focused Sensei reported results from the dose expansion portion of its Phase 1/2 trial evaluating solnerstotug. \"We believe solnerstotug's emerging dose-dependent activity in refractory 'hot' tumors, combined with a favorable tolerability profile, support its advancement into Phase 2 studies,\" the company said at the time.Sensei said on Oct. 30 that it would discontinue development of solnerstotug, review strategic alternatives and implement a workforce reduction.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SNSE":"Sensei Biotherapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Sensei Biotherapeutics股价因收购和私募而飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNSE":1.5},"content_text":"By Josh Beckerman \n\n\n \n\n\nSensei Biotherapeutics shares surged as it acquired Faeth Therapeutics and entered an agreement for a $200 million private placement. \n\n\n  The stock rose 177% to $25.32 and is up about 169% for the past 52 weeks. \n\n\n  Investors include B Group Capital, Balyasny Asset Management, Columbia Threadneedle Investments, Cormorant Asset Management, Fairmount, Logos Capital, RA Capital Management, Vivo Capital and others. \n\n\n  Faeth is developing drugs that target tumor metabolism and signaling. \n\n\n  On Oct. 17, cancer-focused Sensei reported results from the dose expansion portion of its Phase 1/2 trial evaluating solnerstotug. \"We believe solnerstotug's emerging dose-dependent activity in refractory 'hot' tumors, combined with a favorable tolerability profile, support its advancement into Phase 2 studies,\" the company said at the time. \n\n\n  Sensei said on Oct. 30 that it would discontinue development of solnerstotug, review strategic alternatives and implement a workforce reduction. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 18, 2026 13:51 ET (18:51 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}